Dr Reddy stock reports lower Q1 earnings
Published on 10/07/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dr Reddy stock was trading at INR 1,197.40 on the NSE at 1:24 p.m. IST on October 7, 2026, down 0.88 percent from the previous close. The latest quarterly figures show revenue of INR 80.705 billion and net profit of INR 4.435 billion for Q1 FY27.
Q1 profit falls 68.7 percent
According to Sahi Markets on September 17, 2026, Q1 FY27 revenue fell 5.55 percent from INR 85.452 billion in the comparable period. Net profit dropped 68.7 percent to INR 4.435 billion, reflecting inventory write-offs and weaker generic sales.
The same quarter included an INR 2.4 billion provision linked to semaglutide API issues. That charge helps explain why the profit decline was much steeper than the revenue decline, making margin recovery and supply normalization central issues for the next results update.
Pipeline offsets near term pressure
Sahi Markets reported on September 17, 2026 that Dr Reddy entered a royalty-free, non-exclusive licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir. The agreement covers technology transfer and potential supply across 120 low- and lower-middle-income countries.
That opportunity remains linked to the Phase 3 PURPOSE 365 trial and future regulatory approvals, so it does not replace the immediate earnings question. The company's latest website update also lists agreements involving Qdenga and lenacapavir among its strategic development activity.
Analysts see limited upside
According to Marketscreener on September 18, 2026, the consensus rating was Hold among 39 analysts, with an average target of INR 1,267.70. That target lies 5.9 percent above the October 7 price of INR 1,197.40.
A separate CNBC TV18 report dated September 29, 2026 said Citi raised its rating from Sell to Buy and lifted its target from INR 1,040 to INR 1,450. Citi also estimated that Abatacept and Semaglutide could add USD 350 million to USD 400 million to revenue over FY27 through FY29.
Stock remains below yearly high
Dr Reddy stock had a market capitalization of INR 997.4 billion on October 7, 2026, while volume reached 1,059,272 shares. The 52-week range was INR 1,101 to INR 1,414.90, placing the latest price INR 217.50 below the yearly high.
The next concrete checkpoint is the Q2 FY27 result. NSE India lists October 23, 2026 as the date for consideration of the September-quarter financial results.
Dr Reddy stock facts
- Company: Dr. Reddy's Laboratories Limited
- Ticker: DRREDDY
- Trading venue: NSE
- Price (as of October 7, 2026, 1:24 p.m. IST): INR 1,197.40
- Market capitalization: INR 997.4 billion (as of October 7, 2026)
- 52-week range: INR 1,101-1,414.90
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: Nifty 50
Upcoming dates for Dr Reddy stock
- October 23, 2026: Q2 FY27 financial results
